{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"99"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"103"}],"units":"Participants"}],"description":"TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized and treated Part 1 participants only","reportingStatus":"POSTED","timeFrame":"From first dose of study drug in Part 1, up to approximately 83 months","title":"Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}